Buy Or Sell Opportunity • 17h
Now 24% overvalued after recent price rise Over the last 90 days, the stock has risen 1.9% to ₹1,210. The fair value is estimated to be ₹974, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 26%. Buy Or Sell Opportunity • Jun 09
Now 24% overvalued Over the last 90 days, the stock has fallen 3.7% to ₹1,207. The fair value is estimated to be ₹971, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 24% over the last 3 years. Earnings per share has grown by 26%. New Risk • Jun 01
New minor risk - Market cap size The company's market capitalization is less than US$100m. Market cap: ₹9.47b (US$99.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 6.0% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₹9.47b market cap, or US$99.8m). Reported Earnings • May 31
Full year 2026 earnings released: EPS: ₹69.94 (vs ₹55.66 in FY 2025) Full year 2026 results: EPS: ₹69.94 (up from ₹55.66 in FY 2025). Revenue: ₹1.67b (up 74% from FY 2025). Net income: ₹585.9m (up 23% from FY 2025). Profit margin: 35% (down from 49% in FY 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has increased by 45% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • May 30
3B Blackbio Dx Limited Recommends Final Dividend for the Financial Year Ended March 31, 2026 3B Blackbio Dx Limited announced the Board of Directors recommended a final dividend @ 50% i.e. INR 5.00 per equity share of INR 10/- each for the financial year ended March 31, 2026, subject to the approval of the shareholders at the ensuing Annual General Meeting of the Company. Dividend, if approved by the shareholders, will be paid/dispatched within the statutory period as prescribed under Companies Act, 2013. Ankündigung • May 21
3B Blackbio Dx Limited to Report Q4, 2026 Results on May 29, 2026 3B Blackbio Dx Limited announced that they will report Q4, 2026 results on May 29, 2026 Valuation Update With 7 Day Price Move • Apr 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹1,385, the stock trades at a trailing P/E ratio of 20.6x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 218% over the past three years. Valuation Update With 7 Day Price Move • Feb 27
Investor sentiment deteriorates as stock falls 16% After last week's 16% share price decline to ₹1,352, the stock trades at a trailing P/E ratio of 20.2x. Average trailing P/E is 22x in the Chemicals industry in India. Total returns to shareholders of 244% over the past three years. Reported Earnings • Feb 07
Third quarter 2026 earnings released: EPS: ₹26.19 (vs ₹15.75 in 3Q 2025) Third quarter 2026 results: EPS: ₹26.19 (up from ₹15.75 in 3Q 2025). Revenue: ₹559.3m (up 120% from 3Q 2025). Net income: ₹217.3m (up 62% from 3Q 2025). Profit margin: 39% (down from 53% in 3Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 24% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Jan 30
3B Blackbio Dx Limited to Report Q3, 2026 Results on Feb 06, 2026 3B Blackbio Dx Limited announced that they will report Q3, 2026 results on Feb 06, 2026 New Risk • Jan 17
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.8% average weekly change). Valuation Update With 7 Day Price Move • Jan 16
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹1,696, the stock trades at a trailing P/E ratio of 29.5x. Average trailing P/E is 23x in the Chemicals industry in India. Total returns to shareholders of 297% over the past three years. Reported Earnings • Nov 14
Second quarter 2026 earnings released: EPS: ₹17.55 (vs ₹17.35 in 2Q 2025) Second quarter 2026 results: EPS: ₹17.55 (up from ₹17.35 in 2Q 2025). Revenue: ₹394.1m (up 35% from 2Q 2025). Net income: ₹147.1m (flat on 2Q 2025). Profit margin: 37% (down from 50% in 2Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has increased by 49% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Nov 07
3B Blackbio Dx Limited to Report Q2, 2026 Results on Nov 13, 2025 3B Blackbio Dx Limited announced that they will report Q2, 2026 results on Nov 13, 2025 Declared Dividend • Sep 06
Dividend increased to ₹4.00 Dividend of ₹4.00 is 33% higher than last year. Ex-date: 19th September 2025 Payment date: 26th October 2025 Dividend yield will be 0.3%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (7% earnings payout ratio) and cash flows (8% cash payout ratio). The dividend has increased by an average of 38% per year over the past 8 years and payments have been stable during that time. Earnings per share has grown by 5.4% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Sep 04
3B Blackbio Dx Limited, Annual General Meeting, Sep 26, 2025 3B Blackbio Dx Limited, Annual General Meeting, Sep 26, 2025, at 11:30 Indian Standard Time. Reported Earnings • Aug 15
First quarter 2026 earnings released: EPS: ₹14.76 (vs ₹13.19 in 1Q 2025) First quarter 2026 results: EPS: ₹14.76 (up from ₹13.19 in 1Q 2025). Revenue: ₹265.5m (up 37% from 1Q 2025). Net income: ₹125.9m (up 13% from 1Q 2025). Profit margin: 47% (down from 57% in 1Q 2025). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has increased by 66% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Aug 07
3B Blackbio Dx Limited to Report Q1, 2026 Results on Aug 14, 2025 3B Blackbio Dx Limited announced that they will report Q1, 2026 results on Aug 14, 2025 Ankündigung • Jul 28
Trupcr Europe Limited and 3B Blackbio Dx Limited (BSE:532067) entered into a definitive agreement to acquire CorisBioConcept SPRL from Avacta Group Plc (AIM:AVCT) for £2.8 million. Trupcr Europe Limited and 3B Blackbio Dx Limited (BSE:532067) entered into a definitive agreement to acquire CorisBioConcept SPRL from Avacta Group Plc (AIM:AVCT) for £2.8 million on July 28, 2025. The consideration includes upfront cash consideration of £2.15 Million (including net cash & customary working capital adjustments) with an earn-out based on future business performance, of up to £0.615 Million (the “Acquisition”) totaling to £2.765 Million. 3B shall acquire 70% of the total paid-up share capital and TPE shall acquire 30%. For the period ending December 31, 2024, CorisBioConcept SPRL reported total revenue of £5.22 million. The transaction is expected to close on September 10, 2025. Board Change • Jul 22
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Director Harihar Thapak was the last independent director to join the board, commencing their role in 2022. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Jul 11
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.5% average weekly change). Earnings have declined by 13% per year over the past 5 years. Buy Or Sell Opportunity • Jun 03
Now 20% overvalued Over the last 90 days, the stock has fallen 6.2% to ₹1,691. The fair value is estimated to be ₹1,406, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Earnings per share has grown by 17%. Reported Earnings • May 29
Full year 2025 earnings released: EPS: ₹55.66 (vs ₹37.47 in FY 2024) Full year 2025 results: EPS: ₹55.66 (up from ₹37.47 in FY 2024). Revenue: ₹1.12b (up 50% from FY 2024). Net income: ₹476.9m (up 49% from FY 2024). Profit margin: 43% (in line with FY 2024). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has increased by 65% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • May 27
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,970, the stock trades at a trailing P/E ratio of 35.5x. Average trailing P/E is 26x in the Chemicals industry in India. Total returns to shareholders of 484% over the past three years. Ankündigung • May 19
3B Blackbio Dx Limited to Report Q4, 2025 Results on May 28, 2025 3B Blackbio Dx Limited announced that they will report Q4, 2025 results on May 28, 2025 Reported Earnings • Feb 15
Third quarter 2025 earnings released: EPS: ₹15.75 (vs ₹9.94 in 3Q 2024) Third quarter 2025 results: EPS: ₹15.75 (up from ₹9.94 in 3Q 2024). Revenue: ₹253.9m (up 44% from 3Q 2024). Net income: ₹134.0m (up 54% from 3Q 2024). Profit margin: 53% (up from 49% in 3Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 5% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Feb 03
3B Blackbio Dx Limited to Report Q3, 2025 Results on Feb 13, 2025 3B Blackbio Dx Limited announced that they will report Q3, 2025 results on Feb 13, 2025 New Risk • Jan 14
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.1% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. New Risk • Dec 02
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). Valuation Update With 7 Day Price Move • Dec 02
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₹1,934, the stock trades at a trailing P/E ratio of 38.8x. Average trailing P/E is 33x in the Chemicals industry in India. Total returns to shareholders of 308% over the past three years. Reported Earnings • Nov 14
Second quarter 2025 earnings released: EPS: ₹17.35 (vs ₹8.86 in 2Q 2024) Second quarter 2025 results: EPS: ₹17.35 (up from ₹8.86 in 2Q 2024). Revenue: ₹325.8m (up 49% from 2Q 2024). Net income: ₹146.5m (up 87% from 2Q 2024). Profit margin: 45% (up from 36% in 2Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 59% per year, which means it is well ahead of earnings. Ankündigung • Nov 04
3B Blackbio Dx Limited to Report Q2, 2025 Results on Nov 13, 2024 3B Blackbio Dx Limited announced that they will report Q2, 2025 results on Nov 13, 2024 Ankündigung • Sep 25
3B Blackbio Dx Limited Approves Appointment of Rajesh Dubey as an Independent Director 3B Blackbio Dx Limited announced that at its AGM held on 24 September 2024, the shareholders approved appointment of Mr. Rajesh Dubey as an independent director of the company, for a term of five years from 25 September 2024 up to 24 September 2029. Shri. Rajesh Dubey is a post graduate from DAV, Indore. He has over thirty (30) years of experience in sales and marketing in pharma industry. He was associated in past with Leading pharmaceutical companies like Micro Labs Limited, Bangalore and Sterling Labs, Bangalore. Declared Dividend • Sep 04
Dividend increased to ₹3.00 Dividend of ₹3.00 is 20% higher than last year. Ex-date: 17th September 2024 Payment date: 24th October 2024 Dividend yield will be 0.2%, which is lower than the industry average of 0.8%. Sustainability & Growth Dividend is well covered by both earnings (8% earnings payout ratio) and cash flows (10% cash payout ratio). The dividend has increased by an average of 39% per year over the past 7 years and payments have been stable during that time. Earnings per share has grown by 38% over the last 5 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover. Ankündigung • Aug 26
3B Blackbio Dx Limited, Annual General Meeting, Sep 24, 2024 3B Blackbio Dx Limited, Annual General Meeting, Sep 24, 2024, at 11:30 Indian Standard Time. Reported Earnings • Aug 14
First quarter 2025 earnings released: EPS: ₹13.19 (vs ₹9.60 in 1Q 2024) First quarter 2025 results: EPS: ₹13.19 (up from ₹9.60 in 1Q 2024). Revenue: ₹231.3m (up 34% from 1Q 2024). Net income: ₹111.3m (up 77% from 1Q 2024). Profit margin: 48% (up from 37% in 1Q 2024). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 37% per year but the company’s share price has increased by 36% per year, which means it is well ahead of earnings. New Risk • Aug 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.7% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.7% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (14% increase in shares outstanding). Valuation Update With 7 Day Price Move • Aug 01
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹1,257, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 35x in the Chemicals industry in India. Total returns to shareholders of 110% over the past three years. Ankündigung • Jul 30
3B Blackbio Dx Limited to Report Q1, 2025 Results on Aug 12, 2024 3B Blackbio Dx Limited announced that they will report Q1, 2025 results on Aug 12, 2024 New Risk • Jun 11
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.7% average weekly change). Shareholders have been diluted in the past year (14% increase in shares outstanding). Valuation Update With 7 Day Price Move • Jun 11
Investor sentiment improves as stock rises 38% After last week's 38% share price gain to ₹1,158, the stock trades at a trailing P/E ratio of 30.4x. Average trailing P/E is 31x in the Chemicals industry in India. Total returns to shareholders of 167% over the past three years. Reported Earnings • Jun 04
Full year 2024 earnings released: EPS: ₹37.46 (vs ₹34.62 in FY 2023) Full year 2024 results: EPS: ₹37.46 (up from ₹34.62 in FY 2023). Revenue: ₹866.6m (up 26% from FY 2023). Net income: ₹327.3m (up 26% from FY 2023). Profit margin: 38% (in line with FY 2023). Over the last 3 years on average, earnings per share has fallen by 53% per year but the company’s share price has increased by 25% per year, which means it is well ahead of earnings. Ankündigung • May 30
3B Blackbio Dx Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024 3B Blackbio Dx Limited announced that at its meeting of the Board of Directors of the Company held on May 29, 2024, the Board of Directors recommended a final dividend at 30% i.e. INR 3.00 per equity share of INR 10/- each for the financial year ended March 31, 2024, subject to the approval of the shareholders at the up coming Annual General Meeting of the Company. Dividend, if approved by the shareholders, will be paid/dispatched within the statutory period as prescribed under Companies Act, 2013. Ankündigung • May 03
3B Blackbio Dx Limited to Report Q4, 2024 Results on May 29, 2024 3B Blackbio Dx Limited announced that they will report Q4, 2024 results on May 29, 2024 Valuation Update With 7 Day Price Move • Feb 19
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹872, the stock trades at a trailing P/E ratio of 23.6x. Average trailing P/E is 30x in the Chemicals industry in India. Total returns to shareholders of 182% over the past three years. Reported Earnings • Feb 11
Third quarter 2024 earnings released: EPS: ₹9.94 (vs ₹10.27 in 3Q 2023) Third quarter 2024 results: EPS: ₹9.94. Revenue: ₹203.0m (up 15% from 3Q 2023). Net income: ₹87.2m (up 30% from 3Q 2023). Profit margin: 43% (up from 38% in 3Q 2023). The increase in margin was driven by higher revenue. Ankündigung • Jan 18
3B Blackbio Dx Limited to Report Q3, 2024 Results on Feb 09, 2024 3B Blackbio Dx Limited announced that they will report Q3, 2024 results on Feb 09, 2024 Reported Earnings • Nov 12
Second quarter 2024 earnings released: EPS: ₹8.86 (vs ₹11.07 in 2Q 2023) Second quarter 2024 results: EPS: ₹8.86. Revenue: ₹219.3m (up 14% from 2Q 2023). Net income: ₹78.5m (up 6.6% from 2Q 2023). Profit margin: 36% (down from 38% in 2Q 2023). The decrease in margin was driven by higher expenses. Ankündigung • Nov 01
Kilpest India Limited to Report Q2, 2023 Results on Nov 10, 2023 Kilpest India Limited announced that they will report Q2, 2023 results on Nov 10, 2023 New Risk • Oct 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 14% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Shareholders have been diluted in the past year (14% increase in shares outstanding). Market cap is less than US$100m (₹6.02b market cap, or US$72.4m). Ankündigung • Sep 23
Kilpest India Limited Declares Dividend for the Year Ended March 31, 2023 Kilpest India Limited declared dividend if INR 2.5 per share on equity share for the year ended March 31, 2023. Upcoming Dividend • Sep 08
Upcoming dividend of ₹2.50 per share at 0.3% yield Eligible shareholders must have bought the stock before 15 September 2023. Payment date: 22 October 2023. Payout ratio is a comfortable 7.2% and this is well supported by cash flows. Trailing yield: 0.3%. Lower than top quartile of Indian dividend payers (1.3%). Lower than average of industry peers (0.8%). Ankündigung • Aug 28
Kilpest India Limited, Annual General Meeting, Sep 22, 2023 Kilpest India Limited, Annual General Meeting, Sep 22, 2023, at 11:30 Indian Standard Time. Valuation Update With 7 Day Price Move • Aug 18
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to ₹592, the stock trades at a trailing P/E ratio of 17.8x. Average trailing P/E is 25x in the Chemicals industry in India. Total returns to shareholders of 40% over the past three years. Reported Earnings • Aug 12
First quarter 2024 earnings released: EPS: ₹9.60 (vs ₹6.28 in 1Q 2023) First quarter 2024 results: EPS: ₹9.60 (up from ₹6.28 in 1Q 2023). Revenue: ₹172.4m (up 33% from 1Q 2023). Net income: ₹63.0m (up 56% from 1Q 2023). Profit margin: 37% (up from 31% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 43% per year but the company’s share price has increased by 2% per year, which means it is well ahead of earnings. Ankündigung • Aug 03
Kilpest India Limited to Report Q1, 2024 Results on Aug 11, 2023 Kilpest India Limited announced that they will report Q1, 2024 results on Aug 11, 2023 Ankündigung • May 30
Kilpest India Limited Recommends Final Dividend for the Financial Year Ended March 31, 2023 Kilpest India Limited at its board meeting held on May 29, 2023, recommended a final dividend at 25% i.e. INR 2.50 per equity share of INR 10 each for the financial year ended March 31, 2023, subject to the approval of the shareholders at the upcoming Annual General Meeting of the company. The dividend, if approved by the shareholders, will be paid/dispatched within the statutory period as prescribed under the Companies Act, 2013. Reported Earnings • May 30
Full year 2023 earnings released: EPS: ₹34.55 (vs ₹42.98 in FY 2022) Full year 2023 results: EPS: ₹34.55 (down from ₹42.98 in FY 2022). Revenue: ₹690.6m (down 21% from FY 2022). Net income: ₹226.7m (down 30% from FY 2022). Profit margin: 33% (down from 37% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 43% per year, which means it is well ahead of earnings. Valuation Update With 7 Day Price Move • Feb 21
Investor sentiment improves as stock rises 17% After last week's 17% share price gain to ₹454, the stock trades at a trailing P/E ratio of 13x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 448% over the past three years. Reported Earnings • Feb 15
Third quarter 2023 earnings released: EPS: ₹10.27 (vs ₹8.74 in 3Q 2022) Third quarter 2023 results: EPS: ₹10.27 (up from ₹8.74 in 3Q 2022). Revenue: ₹176.1m (up 11% from 3Q 2022). Net income: ₹67.3m (up 17% from 3Q 2022). Profit margin: 38% (up from 36% in 3Q 2022). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has increased by 64% per year, which means it is well ahead of earnings. Ankündigung • Feb 02
Kilpest India Limited to Report Q3, 2023 Results on Feb 14, 2023 Kilpest India Limited announced that they will report Q3, 2023 results on Feb 14, 2023 Reported Earnings • Nov 16
Second quarter 2023 earnings released: EPS: ₹11.07 (vs ₹6.84 in 2Q 2022) Second quarter 2023 results: EPS: ₹11.07 (up from ₹6.84 in 2Q 2022). Revenue: ₹192.7m (up 12% from 2Q 2022). Net income: ₹73.7m (up 43% from 2Q 2022). Profit margin: 38% (up from 30% in 2Q 2022). The increase in margin was primarily driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has increased by 69% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Nov 04
Kilpest India Limited to Report Q2, 2023 Results on Nov 12, 2022 Kilpest India Limited announced that they will report Q2, 2023 results on Nov 12, 2022 Board Change • Oct 31
High number of new directors Independent Non-Executive Director Harihar Thapak was the last director to join the board, commencing their role in 2022. Upcoming Dividend • Sep 07
Upcoming dividend of ₹2.50 per share Eligible shareholders must have bought the stock before 14 September 2022. Payment date: 22 October 2022. Payout ratio is a comfortable 8.6% and this is well supported by cash flows. Trailing yield: 0.7%. Lower than top quartile of Indian dividend payers (1.6%). In line with average of industry peers (0.7%). Ankündigung • Aug 28
Kilpest India Limited, Annual General Meeting, Sep 22, 2022 Kilpest India Limited, Annual General Meeting, Sep 22, 2022, at 11:30 Indian Standard Time. Agenda: To receive, consider and adopt the Audited Standalone Financial Statements of the Company for the financial year ended 31 March 2022 together with the Reports of the Board of Directors and the Auditors thereon; to receive, consider and adopt the Audited Consolidated Financial Statements of the Company for the financial year ended 31st March 2022 together with the Report of the Board of Directors and the Auditors thereon; to appoint a Director in place of Mr. Nikhil Kuber Dubey who retires by rotation and being eligible, offers himself for re-appointment; to approve the declared dividend of 25%, on equity shares for the financial year 2021-22; and to consider the other resolutions. Valuation Update With 7 Day Price Move • Aug 17
Investor sentiment improved over the past week After last week's 20% share price gain to ₹365, the stock trades at a trailing P/E ratio of 14.4x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 350% over the past three years. Reported Earnings • Aug 11
First quarter 2023 earnings released: EPS: ₹6.28 (vs ₹19.89 in 1Q 2022) First quarter 2023 results: EPS: ₹6.28 (down from ₹19.89 in 1Q 2022). Revenue: ₹129.2m (down 62% from 1Q 2022). Net income: ₹40.5m (down 69% from 1Q 2022). Profit margin: 31% (down from 39% in 1Q 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has increased by 62% per year, which means it is tracking significantly ahead of earnings growth. Ankündigung • Aug 02
Kilpest India Limited to Report Q1, 2023 Results on Aug 10, 2022 Kilpest India Limited announced that they will report Q1, 2023 results at 3:30 PM, Indian Standard Time on Aug 10, 2022 Reported Earnings • May 30
Full year 2022 earnings released: EPS: ₹42.89 (vs ₹152 in FY 2021) Full year 2022 results: EPS: ₹42.89 (down from ₹152 in FY 2021). Revenue: ₹875.5m (down 62% from FY 2021). Net income: ₹282.0m (down 75% from FY 2021). Profit margin: 32% (down from 50% in FY 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 53% per year whereas the company’s share price has increased by 56% per year. Ankündigung • May 28
Kilpest India Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022 Kilpest India Limited at its board meeting held on May 27, 2022, recommended a final dividend at 25% i.e. INR 2.50 per equity share of INR 10 each for the financial year ended March 31, 2022, subject to the approval of the shareholders at the upcoming Annual General Meeting of the company. Dividend, if approved by the shareholders, will be paid/dispatched within the statutory period as prescribed under Companies Act, 2013. Board Change • Apr 27
Less than half of directors are independent No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Non Executive Independent Director Abdul Khan was the last independent director to join the board, commencing their role in 2017. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment. Ankündigung • Apr 24
Kilpest India Limited to Report Q4, 2022 Results on May 27, 2022 Kilpest India Limited announced that they will report Q4, 2022 results on May 27, 2022 Valuation Update With 7 Day Price Move • Mar 03
Investor sentiment improved over the past week After last week's 23% share price gain to ₹400, the stock trades at a trailing P/E ratio of 6.8x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 456% over the past three years. Reported Earnings • Feb 11
Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations Third quarter 2022 results: EPS: ₹8.74 (down from ₹26.20 in 3Q 2021). Revenue: ₹159.0m (down 64% from 3Q 2021). Net income: ₹57.5m (down 67% from 3Q 2021). Profit margin: 36% (down from 39% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 72% per year but the company’s share price has increased by 80% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Feb 10
Investor sentiment deteriorated over the past week After last week's 18% share price decline to ₹374, the stock trades at a trailing P/E ratio of 4.8x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 471% over the past three years. Valuation Update With 7 Day Price Move • Jan 04
Investor sentiment improved over the past week After last week's 19% share price gain to ₹517, the stock trades at a trailing P/E ratio of 6.7x. Average trailing P/E is 19x in the Chemicals industry in India. Total returns to shareholders of 469% over the past three years. Ankündigung • Sep 24
Kilpest India Limited Recommends Special Interim Dividend for the Fiscal Year 2021-22 Kilpest India Limited recommended a special interim dividend of INR 8 per equity share of INR 10 each for the Fiscal Year 2021-22. Upcoming Dividend • Sep 07
Upcoming dividend of ₹9.00 per share Eligible shareholders must have bought the stock before 14 September 2021. Payment date: 22 October 2021. Trailing yield: 0.2%. Lower than top quartile of Indian dividend payers (1.5%). Lower than average of industry peers (0.7%). Valuation Update With 7 Day Price Move • Aug 10
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₹534, the stock trades at a trailing P/E ratio of 3.9x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 460% over the past three years. Reported Earnings • Jul 31
First quarter 2022 earnings released The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2022 results: Revenue: ₹342.2m (down 35% from 1Q 2021). Net income: ₹131.6m (down 45% from 1Q 2021). Profit margin: 39% (down from 45% in 1Q 2021). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 122% per year but the company’s share price has only increased by 72% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jul 23
Investor sentiment improved over the past week After last week's 16% share price gain to ₹717, the stock trades at a trailing P/E ratio of 4.7x. Average trailing P/E is 20x in the Chemicals industry in India. Total returns to shareholders of 427% over the past three years. Reported Earnings • Jun 27
Full year 2021 earnings released: EPS ₹152 (vs ₹10.26 in FY 2020) The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: ₹2.30b (up ₹1.99b from FY 2020). Net income: ₹997.9m (up ₹921.0m from FY 2020). Profit margin: 44% (up from 25% in FY 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 57% per year, which means it is significantly lagging earnings growth. Valuation Update With 7 Day Price Move • Jun 26
Investor sentiment improved over the past week After last week's 23% share price gain to ₹532, the stock trades at a trailing P/E ratio of 4.1x. Average trailing P/E is 21x in the Chemicals industry in India. Total returns to shareholders of 295% over the past three years. Valuation Update With 7 Day Price Move • Apr 24
Investor sentiment improved over the past week After last week's 18% share price gain to ₹383, the stock trades at a trailing P/E ratio of 2.9x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 129% over the past three years. Valuation Update With 7 Day Price Move • Apr 07
Investor sentiment improved over the past week After last week's 19% share price gain to ₹338, the stock trades at a trailing P/E ratio of 2.6x. Average trailing P/E is 17x in the Chemicals industry in India. Total returns to shareholders of 155% over the past three years. Is New 90 Day High Low • Feb 26
New 90-day low: ₹281 The company is down 22% from its price of ₹359 on 27 November 2020. The Indian market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. Reported Earnings • Feb 06
Third quarter 2021 earnings released: EPS ₹26.20 (vs ₹2.31 in 3Q 2020) The company reported a strong third quarter result with improved earnings, revenues and profit margins. Third quarter 2021 results: Revenue: ₹442.7m (up ₹373.5m from 3Q 2020). Net income: ₹172.5m (up ₹157.4m from 3Q 2020). Profit margin: 39% (up from 22% in 3Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 115% per year but the company’s share price has only increased by 31% per year, which means it is significantly lagging earnings growth. Ankündigung • Jan 14
Kilpest India Limited to Report Q3, 2021 Results on Feb 05, 2021 Kilpest India Limited announced that they will report Q3, 2021 results on Feb 05, 2021 Valuation Update With 7 Day Price Move • Dec 28
Investor sentiment improved over the past week After last week's 16% share price gain to ₹345, the stock is trading at a trailing P/E ratio of 3.2x, up from the previous P/E ratio of 2.8x. This compares to an average P/E of 18x in the Chemicals industry in India. Total returns to shareholders over the past three years are 205%. Ankündigung • Oct 10
Kilpest India Limited to Report Q2, 2021 Results on Nov 05, 2020 Kilpest India Limited announced that they will report Q2, 2021 results on Nov 05, 2020 Ankündigung • Sep 18
Kilpest India Limited Restructure Its Operation At 3B Blackbio Biotech India Limited Kilpest India Limited intends to integrate the operations of the 3B BLACKBIO BIOTECH INDIA LIMITED with itself as a part of restructuring process by taking over the manufacturing unit along with its business know-how, market reach, all the tangible and intangible assets . Ankündigung • Jul 17
Kilpest India Limited to Report Q1, 2021 Results on Jul 31, 2020 Kilpest India Limited announced that they will report Q1, 2021 results on Jul 31, 2020